Metabolism Platform

GemPharmatech provides animal disease models and genetically humanized models for metabolic diseases, including diabetes mellitus, abnormal lipid metabolism, obesity, and NASH. The company additionally provides a series of in vivo R&D services, with corresponding disease models selected in light of the mechanism of action of the investigational drug.

These models include histopathological analysis, detection of metabolism-related cytokines and inflammatory factors, body weight and food intake, blood glucose, glycosylated haemoglobin (HbA1c), plasma insulin, GTT, and ITT, as well as body composition, bone density, and both indirect and direct metabolic cage tests, which monitor for factors such as CO2  and O2  production, heat, RER and activity, or urine and fecal collection.

英文官网图片修改-02(5)(3).jpg

Data request in progress, please wait…